The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging
Open accessAbstract
Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with 68 Ga-labeled compounds has rapidly become adopted as part of routine clinical care in many parts of the world.However, recent years have witnessed the start of a shift from 68 Ga-to 18 F-labeled PSMA-targeted compounds.The latter imaging agents have several key advantages, which may lay the groundwork for an even more widespread adoption into the clinic.First, facilitated delivery from distant suppliers expands the availability of PET radiopharmaceuticals in smaller hospitals operating a PET center but lacking the patient volume to justify an onsite 68 Ge/ 68 Ga generator.Thus, such an approach meets the increasing demand for PSMA-targeted PET imaging in areas with lower population density and may even lead to cost-savings compared to in-house production.Moreover, 18 F-labeled radiotracers have a higher positron yield and lower positron energy, which in turn decreases image noise, improves contrast resolution, and maximizes the likelihood of detecting subtle lesions.In addition, the longer half-life of 110 min allows for improved delayed imaging protocols and flexibility in study design, which may further increase diagnostic accuracy.Moreover, such compounds can be distributed to sites which are not allowed to produce radiotracers on-site due to regulatory issues or to centers without access to a cyclotron.In light of these advantageous characteristics, 18 F-labeled PSMA-targeted PET radiotracers may play an important role in both optimizing this transformative imaging modality and making it widely available.We have aimed to provide a concise overview of emerging 18 F-labeled PSMA-targeted radiotracers undergoing active clinical development.Given the wide array of available radiotracers, comparative studies are needed to firmly establish the role of the available 18 F-labeled compounds in the field of molecular PCa imaging, preferably in different clinical scenarios.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rowe, S. P., Pienta, K. J., Pomper, M. G., & Gorin, M. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.195255 · Cited by 170
Self-citationWerner, R. A., Bundschuh, R. A., Bundschuh, L., Javadi, M. S., Leal, J. P., Higuchi, T., Pienta, K. J., Buck, A. K., Pomper, M. G., Gorin, M. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.217588 · Cited by 55
Self-citation
Cited by
Zhang, C., Yan, K., Fu, C., Peng, H., Hawker, C. J., & Whittaker, A. K. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00632 · Cited by 493
Molecular imaging in oncology: Current impact and future directions
Rowe, S. P., & Pomper, M. G. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21713 · Cited by 337
Self-citationRadiotheranostics in oncology: Making precision medicine possible
Aboagye, E. O., Barwick, T. D., & Haberkorn, U. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21768 · Cited by 131
Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands
Naik, M., Khan, S. R., Lewington, V., Challapalli, A., Eccles, A., & Barwick, T. D. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae092 · Cited by 10
Metadata
- Authors
- Werner, R. A., Derlin, T., Lapa, C., Sheikbahaei, S., Higuchi, T., Giesel, F. L., Behr, S., Drzezga, A., Kimura, H., Buck, A. K., Bengel, F. M., Pomper, M. G., Gorin, M. A., & Rowe, S. P.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 10
- Issue
- 1
- Pages
- 1-16
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2982404765
- Cited by
- 166
- References
- 2
- FWCI
- 13.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. https://app.cochat.ai/papers/10.7150/thno.37894
- The paper
- Werner, R. A., Derlin, T., Lapa, C., Sheikbahaei, S., Higuchi, T., Giesel, F. L., Behr, S., Drzezga, A., Kimura, H., Buck, A. K., Bengel, F. M., Pomper, M. G., Gorin, M. A., & Rowe, S. P. (2020). 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics. https://doi.org/10.7150/thno.37894
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.